- Market Capitalization, $K 323,510
- Shares Outstanding, K 41,264
- Annual Sales, $ 7,070 K
- Annual Income, $ -106,660 K
- 60-Month Beta 1.09
- Price/Sales 46.02
- Price/Cash Flow N/A
- Price/Book 3.52
|Period||Period Low||Period High||Performance|
| || |
-0.86 (-9.89%)since 05/21/19
| || |
-1.63 (-17.21%)since 03/21/19
| || |
-17.17 (-68.65%)since 06/21/18
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present...
OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
YARDLEY, Pa. (AP) _ OptiNose Inc. (OPTN) on Thursday reported a loss of $28.9 million in its first quarter.
Company reports first quarter 2019 total revenues of $4.5 million.
Kaskela Law LLC announces that it is investigating BioScrip, Inc. ("BioScrip" or the "Company") (Nasdaq: BIOS) on behalf of the Company's shareholders.
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with...
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of NIKE, Inc. (NYSE:NKE), Harley-Davidson,...
Clinical interventions provided by a nutrition support team can prevent hospital readmission in patients with short bowel syndrome (SBS) receiving home parenteral nutrition (PN), saving millions...
Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million